ME-344

Known as: mTOR1/2 Kinase Inhibitor ME-344 
An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
01220152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background This multicenter, open-label, phase Ib study was designed to assess the safety, pharmacokinetics and preliminary… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2016
2016
ME-344 [(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol] is a second-generation derivative natural product… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
The isoflavone ME-344 is a potent anti-cancer agent with preclinical and clinical efficacy in solid tumors. Yet, the mechanism of… (More)
Is this relevant?
Review
2016
Review
2016
Recent evidence highlights that energy requirements of cancer cells vary greatly from normal cells and they exhibit different… (More)
Is this relevant?
2015
2015
Isoflavonoids have been shown to inhibit tumor proliferation and metastasis by activating cell death pathways. As such, they have… (More)
Is this relevant?
2015
2015
BACKGROUND The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?